الإحصائيات الأساسية
| LEI | 549300B66JN3W3J8GH73 |
| CIK | 1612042 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ascendis Pharma A/S - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 13, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princip |
|
| August 13, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. K003583-0002 - 2789-4352-2575.v.3 12 August 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas an |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Second Quarter 2025 Financial Results – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal e |
|
| August 7, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princip |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| July 9, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002 - 2784-7265-2302.v.3 8 July 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparat |
|
| July 9, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 27, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0004 - 2777-3811-8414.v.3 27 June 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and prepara |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 11, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. K003583-0002-2781-7103-7198.v.2 10 June 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and pr |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 9, 2025 |
Exhibit 99.1 COACH Trial Interim Topline Week 26 Data June 9, 2025 Combination treatment with investigational TransCon CNP and TransCon hGH is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of hi |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| May 28, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0004-2765-2561-8446.v.2 27 May 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparatio |
|
| May 28, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 14, 2025 |
Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2024 Exhibit 1.01 Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2024 This Conflict Minerals Report (the “Report”) for Ascendis Pharma A/S (“we,” “our” or “us”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1 to December 31, 2024. Rule 13p-1 requires the disclosure of certai |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ASCENDIS PHARMA A/S (Exact name of registrant as specified in its charter) The Kingdom of Denmark 001-36815 N/A (State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.) Tuborg Boulevard 12 DK-2900 Hellerup, Denmark (Address of principal exec |
|
| May 14, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002-2769-5723-0093.v.4 13 May 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparatio |
|
| May 14, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 1, 2025 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports First Quarter 2025 Financial Results – Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® – TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 – Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, May 1, |
|
| April 29, 2025 |
Exhibit 99.2 Ascendis Pharma A/S Tuborg Boulevard 12 DK-2900 Hellerup Central Business Registration No. 29 91 87 91 Annual Report 2024 (January 1 – December 31) Adopted at the Annual General Meeting of Shareholders on May 27, 2025. Lars Lüthjohan Jensen Chairman of the General Meeting Contents Company Information 3 Statement by Management on the Annual Report 4 Independent Auditor’s Report 5 Manag |
|
| April 29, 2025 |
Notice to convene Annual General Meeting 2025 Exhibit 99.1 Notice to convene Annual General Meeting 2025 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the “Company”) will be held on: May 27th, 2025 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copenhagen K, Denmark The agenda for the annual general meeting is as follows: 1. Election of Chairman of the Meeti |
|
| April 29, 2025 |
Exhibit 99.3 Sustainability & P|ESG Report 2024 www.ascendispharma.com Patients|Environmental, Social and Governance Report (P|ESG) Content Introduction Introduction Progress 03 A message from our Executive Management Team 13 Patients 04 Our Business Model 18 Environmental P|ESG 05 A Brief History 22 Social Approach 07 2024 Sustainability & P|ESG Highlights 28 Governance Ambitions P|ESG Approach P |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| April 9, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002-2781-4383-1309.v.4 8 April 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparati |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| March 28, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0003 - 2761-0440-9612.v.3 28 March 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and prepar |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| March 12, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002 – 2760-0549-9916.v.4 11 March 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and prepar |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 S-8 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title* Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, DKK 1 |
|
| February 27, 2025 |
EX-99.1 Exhibit 99.1 Ascendis Pharma A/S Restricted Stock Unit Program Terms and Conditions, 1 March 2025 1 Introduction and purpose 1.1 The purpose of this document is to set out the general terms and conditions for the Restricted Stock Unit Program (the “RSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply t |
|
| February 27, 2025 |
EX-99.2 Exhibit 99.2 Ascendis Pharma A/S Performance Stock Unit Program Terms and Conditions, 1 March 2025 1 Introduction and purpose 1.1 The purpose of this document is to set out the general terms and conditions for the Performance Stock Unit Program (the “PSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply |
|
| February 12, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002 – 2788-8926-9516.v.2 11 February 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and pre |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 12, 2025 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersig |
|
| February 12, 2025 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, the registration rights agreement entered into in December 2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Ag |
|
| February 12, 2025 |
Exhibit 4.23 CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. Revenue Participation Right Purchase and Sale Agreement By and Between Ascendis Pharma Bone Diseases A/S and Ascendis Pharma A/S and Royalty Ph |
|
| February 12, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-254101, 333-261550, 333-270088, 333-277519, and 333-281916 on Form S-8 and Registration Statement Nos. 333-209336 and 333-282196 on Form F-3 of our report dated Febru |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH |
|
| February 12, 2025 |
Exhibit 4.24 CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. SUPPLY AGREEMENT for manufacture and supply of single chamber cartridges, pre-filled with TransCon PTH [***] assembled [***] effective as of Oc |
|
| February 12, 2025 |
Exhibit 11.1 Contents 1 Purpose 2 2 Scope & Definitions 2 3 Applicability 3 4 Explanation of “Insider Trading” 4 4.1 What is Insider Trading? 4 4.2 What information is “material”? 4 4.3 What is “non-public” information? 5 4.4 Who is an Insider? 5 5 Procedures 5 5.1 Supporting requirements 5 5.2 Prohibition against Insider Trading 7 6 Rule 10b5-1 Trading Plans 10 7 Interpretation, Amendment, and Im |
|
| February 12, 2025 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results – Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025 – SKYTROFA® full year |
|
| February 12, 2025 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jan Møller Mikkelsen, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 12, 2025 |
(Page remainder left blank intentionally, immediately followed by the signatures page.) Exhibit 4.25 CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. THIS AMENDMENT NUMBER 1 (“Amendment”), of the Supply Agreement effective as of October 1st, 2022 (such agreement, as amended from time to time, |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 12, 2025 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned |
|
| February 12, 2025 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Scott T. Smith, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| February 12, 2025 |
Exhibit 4.2(b) WARRANT CERTIFICATE (non-negotiable instrument) Ascendis Pharma A/S (cvr.no. 2991 8791), with its principal business address at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark (hereinafter referred to as “Ascendis Pharma”), has on 09/12/2021 issued this Warrant Certificate to NAME (hereinafter referred to as the “Warrantholder”) whereby the Warrantholder without payment has received |
|
| January 15, 2025 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. K003583-0002 – 2782-4021-9659.v.4 14 January 2025 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and prep |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| January 13, 2025 |
Exhibit 99.1 Ascendis Pharma A/S J.P. Morgan Healthcare Conference San Francisco January 2025 For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 30, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74562 - 2771-4320-5387.v.3 20 December 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparatio |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 11, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 2766-4912-4107.v.4 10 December 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparatio |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| November 14, 2024 |
SC 13G/A 1 tm2427451d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 15)* Ascendis Pharma A/S (Name of Issuer) American Depository Shares representing Ordinary Shares of Ascendis Pharma A/S (Title of Class of Securities) 04351P101 (CUSIP Number) September 30, 2024 (Date of Event Wh |
|
| November 14, 2024 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Third Quarter 2024 Financial Results – YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025 – SKYTROFA Q3 revenue of €47.2 million – 60%+ year-over-year volu |
|
| November 14, 2024 |
EX-99.1 2 tm2427451d12ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
SC 13G/A 1 p24-3105sc13ga.htm ASCENDIS PHARMA A/S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ascendis Pharma A/S (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 04351P101** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| November 13, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 2764-9756-9291.v.2 12 November 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparatio |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| November 12, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Ascendis Pharma A/S (Name of Issuer) American Depositary Shares (Title of Class of Securit |
|
| November 12, 2024 |
EX-99.1 2 d897450dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 11/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTI |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Ascendis Pharma A/S is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Ascendis Pharma A/S (Name of Issuer) Common Stock (Title of Class of Securities) 04351P101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 4, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| October 9, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 392 8 October 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combat |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 27, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74561 - 865 27 September 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the com |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 23, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 23, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 3.1 REF. 74561 - 432 19 September 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the com |
|
| September 23, 2024 |
Exhibit 1.1 ASCENDIS PHARMA A/S (a company organized under the laws of Denmark) 2,000,000 American Depositary Shares Representing an Aggregate of 2,000,000 Ordinary Shares UNDERWRITING AGREEMENT September 19, 2024 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Evercore Group L.L.C. Goldman Sachs & Co. LLC as Representatives of the several Underwriters to be named in the within-mentioned Under |
|
| September 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares, DKK 1 nominal value per share (2) Rule 457(r) 2,300,000 (3) $150. |
|
| September 20, 2024 |
2,000,000 American Depositary Shares representing 2,000,000 ordinary shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-282196 Prospectus supplement (To prospectus dated September 18, 2024) 2,000,000 American Depositary Shares representing 2,000,000 ordinary shares We are offering 2,000,000 American Depositary Shares, or ADSs, representing ordinary shares of Ascendis Pharma A/S. Each ADS will represent one issued ordinary share. The ADSs, repre |
|
| September 18, 2024 |
Ascendis Pharma A/S Dated as of ___________, 20___ Exhibit 4.4 Ascendis Pharma A/S INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment |
|
| September 18, 2024 |
EX-5.1(a) Exhibit 5.1(a) Mazanti-Andersen Advokatpartnerselskab VAT: DK35892052 Amaliegade 10 DK-1256 København K +45 3314 3536 www.mazanti.dk Klosterbakken 12 DK-5000 Odense C +45 6314 1414 Ascendis Pharma A/S Tuborg Boulevard 12 2900 Hellerup 18.9.2024 Ref. 58917/LLJ ID 2451 Exhibit 5.1 Re. Registration with the U.S. Securities and Exchange commission of securities of the Issuer Lars Lüthjohan J |
|
| September 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Ca |
|
| September 18, 2024 |
Subject to completion, dated September 18, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-282196 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying prospectus is an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
EX-5.1(b) Exhibit 5.1(b) 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris September 18, 2024 Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv Ascend |
|
| September 16, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 16, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 16, 2024 |
EX-99.1 TransCon™ CNP (navepegritide) ApproaCH Trial Topline Results September 16, 2024 TransCon CNP is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.1 Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of histori |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 11, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 295 10 September 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the com |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 4, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title* Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, DKK 1 n |
|
| September 4, 2024 |
As filed with the Securities and Exchange Commission on September 3, 2024 S-8 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No. |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 3, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 3, 2024 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Second Quarter 2024 Financial Results – YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adults – TransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeks – SKYTROFA Q2 revenue of €26 million – 134% year-over-year volume growth offse |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal e |
|
| August 14, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 256 13 August 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combat |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal e |
|
| July 10, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 203 9 July 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combating |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 28, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 163 11 June 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combatin |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exe |
|
| June 12, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 163 11 June 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combatin |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 31, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 58917 - 4128 30 May 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combatin |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ASCENDIS PHARMA A/S (Exact name of registrant as specified in its charter) The Kingdom of Denmark 001-36815 N/A (State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal execu |
|
| May 29, 2024 |
Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2023 Exhibit 1.01 Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2023 This Conflict Minerals Report (the “Report”) for Ascendis Pharma A/S (“we,” “our” or “us”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1 to December 31, 2023. Rule 13p-1 requires the disclosure of certai |
|
| May 16, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 137 15 May 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combating |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 2, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 2, 2024 |
Notice to convene Annual General Meeting 2024 Exhibit 99.1 Notice to convene Annual General Meeting 2024 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the “Company”) will be held on: May 30th, 2024 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copenhagen K, Denmark The agenda for the annual general meeting is as follows: 1. Election of Chairman of the Meeti |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal exec |
|
| May 2, 2024 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports First Quarter 2024 Financial Results – Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 – TransConTM PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch plann |
|
| May 2, 2024 |
Exhibit 99.2 Ascendis Pharma A/S Tuborg Boulevard 12 DK-2900 Hellerup Central Business Registration No. 29 91 87 91 Annual Report 2023 (January 1 – December 31) Adopted at the Annual General Meeting of Shareholders on May 30, 2024. Lars Lüthjohan Jensen Chairman of the General Meeting 2 Contents Company Information 3 Statement by Management on the Annual Report 4 Independent Auditor’s Report 6 M |
|
| May 2, 2024 |
Exhibit 99.3 Sustainability & P|ESG Report 2023 www.ascendispharma.com Welcome to the Ascendis Pharma Sustainability & P|ESG Report 2023 4 A message from our Executive Management Team 5 Our Business 8 Sustainability & P|ESG Highlights 2023 10 Our Sustainability & P|ESG Approach 16 Patients 24 Environmental 30 Social 38 Governance 48 Sustainability & P|ESG Ambitions 2024 As part of the Ascendis Pha |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| April 10, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 97 9 April 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combating |
|
| April 10, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| March 27, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74559 - 2316 26 March 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combat |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| March 14, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 56 12 March 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combatin |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| February 29, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title* Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, DKK 1 |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 29, 2024 |
Exhibit 99.2 Ascendis Pharma A/S Performance Stock Unit Program Terms and Conditions, 1 March 2024 1 Introduction and purpose 1.1 The purpose of this document is to set out the general terms and conditions for the Performance Stock Unit Program (the “PSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply to all |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 14, 2024 |
EX-1 2 tm246065d4ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 14, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 74533 - 16 13 February 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comba |
|
| February 14, 2024 |
SC 13G/A 1 p24-0273sc13ga.htm ASCENDIS PHARMA A/S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ascendis Pharma A/S (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 04351P101** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| February 14, 2024 |
SC 13G/A 1 tm246065d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 14)* Ascendis Pharma A/S (Name of Issuer) American Depository Shares representing Ordinary Shares of Ascendis Pharma A/S (Title of Class of Securities) 04351P101 (CUSIP Number) December 31, 2023 (Date of Event Which |
|
| February 14, 2024 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
EX-99.1 2 d752941dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez* ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTISA |
|
| February 12, 2024 |
SC 13G/A 1 d752941dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 4)* Ascendis Pharma A/S (Name of Issuer) American Depositary Shares (Title of C |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Ascendis Pharma A/S (Name of Issuer) Common Stock (Title of Class of Securities) 04351P101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| February 7, 2024 |
Exhibit 11.1 Insider Trading Compliance Policy Contents 1 Purpose 4 2 Scope & Definitions 4 3 Applicability 5 4 Explanation of “Insider Trading” 6 4.1 What is Insider Trading? 6 4.2 What information is “material”? 6 4.3 What is “non-public” information? 7 4.4 Who is an Insider? 7 5 Procedures 7 5.1 Supporting requirements 7 5.2 Prohibition against Insider Trading 9 6 Documentation 11 7 Rule 10b5-1 |
|
| February 7, 2024 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned |
|
| February 7, 2024 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersig |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH |
|
| February 7, 2024 |
Exhibit 97.1 Contents 1 Persons Subject to Policy 3 2 Compensation Subject to Policy 3 3 Recovery of Compensation 3 4 Manner of Recovery; Limitation on Duplicative Recovery 3 5 Administration 4 6 Interpretation 4 7 No Indemnification; No Personal Liability 4 8 Application; Enforceability 4 9 Severability 5 10 Amendment and Termination 5 11 Definitions 5 12 Change Log 7 Ascendis Pharma A/S (the “Co |
|
| February 7, 2024 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results – Launch of TransConTM PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024 – TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024 – Total Q4 revenue of €138 million including SKYTROFA® revenue of €64 million; Q4 operating expenses of |
|
| February 7, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550 and 333-270088 on Form S-8 and Registration Statement Nos. 333-209336, 333-211511, 333-216882, 333-223134, 333-225284 and 333-256571 on Form F-3 of |
|
| February 7, 2024 |
Exhibit 4.22 [***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH OMITTED INFORMATION AS PRIVATE OR CONFIDENTIAL, AND SUCH INFORMATION IS NOT MATERIAL. Revenue Participation Right Purchase and Sale Agreement By and Between Ascendis Pharma Endocrinology Division A/S and Ascendis Pharma A/S and Roy |
|
| February 7, 2024 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jan Møller Mikkelsen, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat |
|
| February 7, 2024 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Scott T. Smith, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| February 7, 2024 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, the registration rights agreement entered into in December 2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Ag |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASCENDIS PHARMA A S SPONSORED (Name of Issuer) Common Stock (Title of Class of Securities) 04351P101 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 31, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of p |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| January 10, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 71698 - 634 9 January 2024 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combat |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| January 8, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princi |
|
| January 8, 2024 |
Ascendis Pharma A/S 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 For investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.1 Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements |
|
| January 8, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princi |
|
| January 2, 2024 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 73818 - 754 27 December 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comb |
|
| January 2, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| December 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| December 19, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| December 13, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 73818 - 566 12 December 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comb |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| November 29, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of |
|
| November 29, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of |
|
| November 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| November 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| November 16, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 71698 - 514 14 November 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comb |
|
| November 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princ |
|
| November 7, 2023 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Third Quarter 2023 Financial Results – European Commission decision for TransCon™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024 – TransCon PTH NDA resubmission to FDA expected before mid-November – Completed enrollment in the Phase 3 ApproaCH Trial; initiated TransCon CNP infant trial in the t |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| October 11, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princi |
|
| October 11, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 71698 - 490 10 October 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comba |
|
| September 29, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 73463 - 925 28 September 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the com |
|
| September 29, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 14, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 13, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 13, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 71698 - 435 12 September 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for |
|
| September 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of prin |
|
| September 5, 2023 |
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Second Quarter 2023 Financial Results – Expect to resubmit NDA to FDA for TransCon™ PTH in October 2023; EC decision on MAA for TransCon PTH expected during the fourth quarter of 2023 – U.S. and EU regulatory authorities endorsed ApproaCH as a pivotal Phase 3 trial of TransCon CNP in children with achondroplasia; enrollment completed, and topline |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| August 9, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of princip |
|
| August 9, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Exhibit 1.1 REF. 71698 - 395 8 August 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combati |
|
| July 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| July 12, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 71698 - 340 11 July 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the c |
|
| June 30, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 72543 - 500 26 June 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the c |
|
| June 30, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 20, 2023 |
EX-99.1 Long-Term Efficacy and Safety of TransCon™ PTH in Adults with Hypoparathyroidism: 52-Week Results From the Open-Label Extension of the Phase 3 PaTHway Trial Presented at ENDO 2023 June 17, 2023 Exhibit 99.1 Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentat |
|
| June 14, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 71698 - 279 13 June 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the c |
|
| June 14, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| June 1, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 72543 - 362 24 May 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the co |
|
| May 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 31, 2023 |
EX-99.1 Ascendis Pharma A/S Oncology Program Update May 31, 2023 Exhibit 99.1 Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our prospective product candidates; clinical trial results; the expected timing of future clinical tria |
|
| May 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 30, 2023 |
Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2022 EX-1.01 Exhibit 1.01 Ascendis Pharma A/S Conflict Minerals Report For The Calendar Year Ended December 31, 2022 This Conflict Minerals Report (the “Report”) for Ascendis Pharma A/S (“we” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1 to December 31, 2022. Rule 13p-1 requires the disclosure of cert |
|
| May 30, 2023 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ASCENDIS PHARMA A/S (Exact name of registrant as specified in its charter) The Kingdom of Denmark 001-36815 N/A (State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| May 11, 2023 |
Articles of Association Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) EX-1.1 Exhibit 1.1 REF. 71698-191 9 May 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the comba |
|
| May 11, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 2, 2023 |
EX-99.2 Exhibit 99.2 Ascendis Pharma A/S Tuborg Boulevard 12 DK-2900 Hellerup Central Business Registration No. 29 91 87 91 Annual Report 2022 (January 1 – December 31) Adopted at the Annual General Meeting of Shareholders on , 2023. Lars Lüthjohan Jensen Chairman of the General Meeting 2 Contents Company Information 3 Statement by Management on the Annual Report 4 Independent Auditor’s Report 6 M |
|
| May 2, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| May 2, 2023 |
Notice to convene Annual General Meeting 2023 EX-99.1 Exhibit 99.1 Notice to convene Annual General Meeting 2023 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the “Company”) will be held on: May 30th, 2023 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copenhagen K, Denmark The agenda for the annual general meeting is as follows: 1. Election of Chairman of t |
|
| May 2, 2023 |
EX-99.3 Exhibit 99.3 SUSTAINABILITY & PATIENTS | ENVIRONMENTAL, SOCIAL, GOVERNANCE REPORT 2022 P|ESG As part of the Ascendis Pharma A/S 2022 Annual Report, this report outlines the Sustainability and, what we refer to as, Patients|Environmental, Social, and Governance (P|ESG) reporting activities for all Ascendis Pharma Group entities. Previous years, this report was known as our Corporate Respons |
|
| May 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal ex |
|
| April 27, 2023 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports First Quarter 2023 Financial Results – Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible – 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded Access Program continues to enroll new patients – SKYTROFA®* revenue reached €31.6 million in the first qu |
|
| April 27, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| April 12, 2023 |
EX-1.1 Exhibit 1.1 REF. 71698 – 150 11 April 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the |
|
| April 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| April 10, 2023 |
ASND / Ascendis Pharma A/S - ADR / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2312250d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 13)* Ascendis Pharma A/S (Name of Issuer) American Depository Shares representing Ordinary Shares of Ascendis Pharma A/S (Title of Class of Securities) 04351P101 (CUSIP Number) April 6, 2023 (Date of Event Which Re |
|
| April 3, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| March 30, 2023 |
Exhibit 1.1 REF. 71708 - 941 30 March 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combati |
|
| March 30, 2023 |
6-K 1 d487145d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark |
|
| March 15, 2023 |
EX-1.1 Exhibit 1.1 REF. 71698 - 99 14 March 2023 Articles of Association of Ascendis Pharma A/S (CVR-nr. 29918791) (Registration no 29918791) Name, Registered Office and Objects of the Company: Article 1 The company’s name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the c |
|
| March 15, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| March 13, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| March 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principa |
|
| February 28, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ascendis Pharma A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title* Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary |
|
| February 28, 2023 |
Ascendis Pharma A/S Performance Stock Unit Program. EX-99.3 Exhibit 99.3 Ascendis Pharma A/S Performance Stock Unit Program Terms and Conditions, 1 March 2023 1 Introduction and purpose 1.1 The purpose of this document is to set out the general terms and conditions for the Performance Stock Unit Program (the “PSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 S-8 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Ascendis Pharma A/S Restricted Stock Unit Program EX-99.2 Exhibit 99.2 Ascendis Pharma A/S Restricted Stock Unit Program Terms and Conditions, 1 March 2023 1 Introduction and purpose 1.1 The purpose of this document is to set out the general terms and conditions for the Restricted Stock Unit Program (the “RSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply t |
|
| February 16, 2023 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersig |
|
| February 16, 2023 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Ascendis Pharma A/S (the “Company”) for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH |
|
| February 16, 2023 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Scott T. Smith, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| February 16, 2023 |
Description of Share Capital and American Depositary Shares. Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, the registration rights agreement entered into in December 2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Ag |
|
| February 16, 2023 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jan Møller Mikkelsen, certify that: 1. I have reviewed this annual report on Form 20-F of Ascendis Pharma A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat |
